TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33649979
Drug: Higher dosing
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosing regimen (> 4000 IU)
Study: 34912512
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (80 mg)
Study: 36463724
Drug: GRASP (GRoup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRASP (GRoup trAining for Social skills in Psychosis) plus treatment-as-usual (TAU)
Study: 33875426
Drug: Clofazimine 300
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine 300 mg daily for 3 days, followed by 100 mg daily for 11 days
Study: 33875426
Drug: Clofazimine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine (loading doses of 200 and 300 mg)
Study: 35671089
Drug: Reported daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reported daily use of mobile phones
Study: 35671089
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment uptake
Study: 34383903
Drug: Pecan consumption
Normalized name: Pecan
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan consumption (68 g) as part of a free-living diet (ADD group, n = 16)
Study: 34383903
Drug: Pecan substitution
Normalized name: Pecan
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan substitution (68 g) for isocaloric foods (SUB group, n = 18)
Study: 34980232
Drug: ANC counseling
Normalized name: ANC-501
DrugBank: ANC-501 (DB18907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANC counseling plus BEP supplement
Study: 34980232
Drug: ANC counseling
Normalized name: ANC-501
DrugBank: ANC-501 (DB18907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANC counseling plus BEP supplement plus 2 doses azithromycin
Study: 34980232
Drug: ANC counseling
Normalized name: ANC-501
DrugBank: ANC-501 (DB18907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANC counseling plus BEP supplement plus daily single dose of nicotinamide and choline
Study: 35321739
Drug: Prediction-aided decisions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction-aided decisions during bDMARD tapering
Study: 32618436
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with high-risk regimens including cisplatin or carboplatin and doxorubicin (19 patients), or cisplatin or carboplatin alone (3 patients)
Study: 34544324
Drug: Pregabalin and
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin and exercise therapy
Study: 35654972
Drug: Liraglutide (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (a GLP‐1 receptor agonist)
Study: 32767766
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium for oral solution (50 mg)
Study: 32727733
Drug: 30% fluence
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% fluence rate of photodynamic therapy (PDT)
Study: 32727733
Drug: 40% fluence
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% fluence rate of photodynamic therapy (PDT)
Study: 32727733
Drug: 50% fluence
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% fluence rate of photodynamic therapy (PDT)
Study: 35352703
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy intervention teaching pain self-management skills in 12 weekly, 90-minute groups
Study: 35352703
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy intervention
Study: 33972581
Drug: Citric-acid dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citric-acid dialysate (C1.5) with dCa of 1.50 mmol/l
Study: 33972581
Drug: Acetic-acid dialysate
Normalized name: Acetic Acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetic-acid dialysate with dCa of 1.25 mmol/l (A1.25)
Study: 33972581
Drug: Acetic-acid dialysate
Normalized name: Acetic Acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetic-acid dialysate with dCa of 1.50 mmol/l (A1.5)
Study: 33417730
Drug: Daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 50 mg once daily for 5 consecutive days
Study: 36293971
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g/kg body weight)
Study: 34388379
Drug: Bevacizumab (VEGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (VEGF inhibitor) added to Erlotinib (EGFR inhibitor)
Study: 34388379
Drug: Erlotinib (EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (EGFR inhibitor) alone
Study: 34208829
Drug: Chemical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical agents acting on RBC membrane channels
Study: 34208829
Drug: Recombinant Annexin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Annexin V pre-treatment
Study: 34208829
Drug: Modulators of
Normalized name: SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modulators of RBC membrane channels (activating Piezo1 Ca2+ channel)
Study: 34810363
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with education for self‐management and counseling
Study: 33109641
Drug: IA injection
Normalized name: factor VIIa Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA injection of HA+CS combined with duloxetine
Study: 33109641
Drug: IA injection
Normalized name: factor VIIa Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA injection of HA+CS alone
Study: 35030257
Drug: Escalated antiarrhythmic
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated antiarrhythmic drug therapy (specifically amiodarone)
Study: 34160595
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus psychosocial treatment
Study: 34160595
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication plus psychosocial treatment
Study: 35058236
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg CC-90001
Study: 35058236
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg CC-90001
Study: 35058236
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg CC-90001 (PF-ILD substudy)
Study: 32998924
Drug: Topical natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical natamycin 5%
Study: 33045374
Drug: 10% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% daily contrast increment protocol
Study: 33045374
Drug: 5% daily
Normalized name: NaFrinse 0.05% Daily Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% daily contrast increment protocol
Study: 33045374
Drug: 0% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% daily contrast increment protocol
Study: 32803888
Drug: Lindera strychnifolia
Normalized name: Lindera aggregata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lindera strychnifolia root extract (LsR) treatment for 83 days
Study: 32803888
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (AGA subjects without treatment)
Study: 36081953
Drug: QL1209 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1209 420 mg intravenously
Study: 36081953
Drug: Perjeta® 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perjeta® 420 mg intravenously
Study: 34228875
Drug: 10-mg oral
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-mg oral solution oxycodone
Study: 34228875
Drug: 20-mg controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg controlled-release (water-swellable or lipid-based) oxycodone
Study: 32092187
Drug: LCP‐tac and
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCP‐tac and everolimus once daily
Study: 35835346
Drug: Ward-based goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ward-based goal-directed fluid therapy (GDFT)
Study: 34520293
Drug: Existing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing treatment comparison tests under non-proportional hazards
Study: 35638455
Drug: 30% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% NaCl solution
Study: 36088270
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen (10mg/kg/6h)
Study: 36088270
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (0.5mg/kg/6h)
Study: 32147962
Drug: Cash transfers
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash transfers and monthly group nutrition education sessions led by community health volunteers
Study: 33836388
Drug: Topical ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketamine cream 10%
Study: 33836388
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g of cold cream)
Study: 33508845
Drug: Predialytic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predialytic oral nutritional supplements (ONS) (450 kcal energy, 20 g protein) administered 1 hour prior to dialysis
Study: 33508845
Drug: Intradialytic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic oral nutritional supplements (ONS) (450 kcal energy, 20 g protein) administered after 2 hours of dialysis
Study: 35172685
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin plus chemotherapy (A + CHP)
Study: 34514706
Drug: Solution-Focused Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-Focused Support Program (SFSP), 4 sessions of online support, 1 session per week
Study: 32169003
Drug: Support group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support group for typically developing siblings; details on dosage and duration not available.
Study: 32169003
Drug: Similar group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar group without a focus on the sibling with autism spectrum disorder; details on dosage and duration not available.
Study: 32116139
Drug: Artificial food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial food coloring (AFC) 225 mg in chocolate cookies for 3 days
Study: 33964196
Drug: Epidural solution
Normalized name: Lidocaine Hydrochloride 1% Epidural Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural solution of bupivacaine 1 mg mL-1, fentanyl 2 μg mL-1 with adrenaline 2 μg mL-1
Study: 33964196
Drug: Epidural solution
Normalized name: Lidocaine Hydrochloride 1% Epidural Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural solution of bupivacaine 1 mg mL-1, fentanyl 2 μg mL-1 without adrenaline
Study: 35674835
Drug: Ticagrelor (180-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180-mg loading dose)
Study: 35674835
Drug: Clopidogrel (600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600-mg loading dose)
Study: 35148516
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg oral tamsulosin for 5 days preoperatively and 2 days postoperatively
Study: 32041658
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 4-6 µg/kg
Study: 32041658
Drug: Glycopyrronium bromide
Normalized name: Glycopyrronium bromide
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glycopyrronium bromide 4 µg/kg (active placebo)
Study: 35971150
Drug: e‐cigarettes with
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐cigarettes with 18 mg/ml nicotine
Study: 39423145
Drug: Deucravacitinib 12
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 12 mg
Study: 35182043
Drug: Deucravacitinib 36
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 36 mg
Study: 33118927
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTi), n = 72
Study: 33118927
Drug: No-treatment control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control, n = 73
Study: 35671086
Drug: NRD.E1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRD.E1 at 40 mg/day
Study: 35671086
Drug: NRD.E1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRD.E1 at 150 mg/day
Study: 33548056
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support pre-treatment
Study: 36309984
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Simvastatin and Ezetimibe
Study: 33649098
Drug: Rituximab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1 g) on days 1 and 15
Study: 33389614
Drug: Combined mammography
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined mammography and adjunctive ultrasound
Study: 35517806
Drug: Crocin supplementation
Normalized name: crocin
DrugBank: Crocin (DB11874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin supplementation (30 mg/day for 12 weeks)
Study: 34991056
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) at 10-30 mg/kg/day
Study: 34991056
Drug: Placebo (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (previous treatment)
Study: 33512065
Drug: KHK4083 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4083 (10 mg/kg, single intravenous dose)
Study: 33512065
Drug: KHK4083 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4083 (multiple intravenous doses)
Study: 36346336
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion management
Study: 33767376
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein regimen (18% energy intake as amino acids, targeting 4 g/kg/day)
Study: 33767376
Drug: Conventional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen (12.5% energy intake as amino acids, targeting 3 g/kg/day)
Study: 34461161
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral thiamine (one gram twice daily)
Study: 34729774
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus the interprofessional student-run medication review program (ISP)
Study: 34488269
Drug: Narrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative therapy (once a week for 30 min over 6 weeks)
Study: 34488269
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine clinical treatment)
Study: 35166608
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment plus virtual reality exercises with the Nintendo Wii console (n=36)
Study: 35166608
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment (control group, n=37)
Study: 33588078
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (2000 IU daily)
Study: 32639634
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (10 mg/kg daily)
Study: 32639634
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (5 mg/kg daily)
Study: 32981056
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 0.5 mg/kg ketamine followed by continuous infusion of 5 μg/kg/min (K1 group)
Study: 32981056
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 0.5 mg/kg ketamine followed by continuous infusion of 10 μg/kg/min (K2 group)
Study: 32981056
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 0.5 mg/kg ketamine followed by continuous infusion of 20 μg/kg/min (K3 group)
Study: 36066501
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA) injections
Study: 35007748
Drug: Crimson duvet
Normalized name: crimson bottlebrush pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crimson duvet procedure (CDP) with microfracture treatment of the footprint
Study: 35090154
Drug: Suppressive valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive valacyclovir treatment for 1 year
Study: 33749386
Drug: G-computation method
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-computation method
Study: 33753652
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel combined with calcium hydroxide (CH + CHX) for 1 week
Study: 33753652
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel combined with calcium hydroxide (CH + CHX) for 2 weeks
Study: 33753652
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel combined with calcium hydroxide (CH + CHX) for 3 weeks
Study: 36330051
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene Blue (MB) injection
Study: 34534517
Drug: Voluntary daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary daily lateral flow device (LFD) testing for 7 days with LFD-negative contacts remaining at school
Study: 32270638
Drug: Simple manipulative
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple manipulative therapy
Study: 36148467
Drug: Avidekel oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avidekel oil (30% cannabidiol and 1% tetrahydrocannabinol: 295 mg and 12.5 mg per ml)
Study: 34243808
Drug: Self-administered mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered mirror therapy (MT) education in addition to regular rehabilitation interventions for 4 weeks
Study: 35380419
Drug: Ferric pyrophosphate
Normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric pyrophosphate citrate (FPC) administered as a single intravenous dose of 6.5 mg to healthy subjects.
Study: 35380419
Drug: Ferric pyrophosphate
Normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric pyrophosphate citrate (FPC) administered at two sequential hemodialysis treatments: HD dose 1 (27.2 mg at 95 μg/L for 4 h) and HD dose 2 (6.5 mg via pre-dialyzer blood circuit).
Study: 35380419
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of PK parameters between HD dose 1 and HD dose 2.
Study: 32560739
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of active ZHWFG three times daily
Study: 32560739
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of active ZHWFG plus 5 g of ZHWFG‐matched placebo three times daily
Study: 32560739
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of ZHWFG‐matched placebo three times daily
Study: 33876784
Drug: Epidural blockade
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blockade with 0, 50, 100 or 150 mg of epidural ropivacaine
Study: 33876784
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at concentrations up to 6 μg ml-1
Study: 33876784
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epidural anaesthesia and intravenous propofol
Study: 33586626
Drug: Initial Aqualizer™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial Aqualizer™ therapy (Group 1)
Study: 33586626
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial therapy (Group 2)
Study: 32448382
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily Biphasic Human Insulin 30 (BHI 30)
Study: 32448382
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily Biphasic Human Insulin 30 (BHI 30)
Study: 35430718
Drug: Aerosolized capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized capsaicin (AC), 1-10 drops of liquid cayenne extract (1.5-2% capsaicin) in 100 mL carbonated water.
Study: 33275318
Drug: Imeglimin 500
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 500 mg
Study: 33275318
Drug: Imeglimin 1500
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 1500 mg